je.st
news
Tag: merck
Merck to Present at the Morgan Stanley Global Healthcare Conference
2013-09-10 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Roger M. Perlmutter, executive vice president and president, Merck Research Laboratories, is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Sept. 11 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html. Language: English Contact: MerckMedia:Kelley P. Dougherty, 908-423-4291orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
global
conference
morgan
Merck Animal Health Introduces Next Generation of Circovirus Protection
2013-09-10 06:00:00| National Hog Farmer
Merck Animal Health has introduced the first porcine circovirus Type 2 (PCV2) vaccine, Circumvent PCV G2, for use in pigs as early as 3 days of age in a one- or two-dose formulation. The vaccine offers five-month duration of immunity (DOI), which the company claims is at least 25% longer than any other PCV2 vaccine on the market. read more
Tags: health
protection
generation
animal
Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment
2013-09-09 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042orTina Grasso, 267-893-9783orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
treatment
drug
acceptance
Merck and Israels Maccabi Healthcare to Leverage Unique Real-World Database to Inform Novel Health Approaches
2013-09-09 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. and TEL AVIV, ISRAEL Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Maccabi Healthcare Services, atwo million-member health care provider in Israel, are starting a new, multi-yearagreement to leverage real-world data from Maccabis unique longitudinal database to inform novel, patient-centered health approaches. Maccabi and Merck will apply technical and information research capabilities to draw insights from Maccabis data to support personalized health care delivery strategies across several therapeutic areas, including prevalent and costly chronic diseases. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: health
unique
database
approaches
Pfizer Inc. (PFE), Gilead Sciences, Inc. (GILD), Merck & Co., Inc....
2013-08-27 16:30:04| Biotech - Topix.net
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors.
Tags: inc
sciences
merck
pfizer
Sites : [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] next »